CAR-T-Zell-Therapie in der Rheumatologie – Was wissen wir bisher?

Hagen M, Wirsching A, Bohr D, Taubmann J, Müller F, Mackensen A, Grieshaber Bouyer R, Schett G (2024)

Publication Type: Journal article

Publication year: 2024

Journal

Zeitschrift für Rheumatologie Springer Verlag

Abstract

Autoreactive B‑cells play a key role in the pathogenesis of autoimmune diseases, such systemic lupus erythematosus (SLE). An efficient depletion of B‑cells therefore plays a special role in autoimmune diseases, especially in cases with a severe course of the disease. Treatment with chimeric antigen receptor (CAR) T‑cells, which was originally developed for the treatment of B‑cell lymphomas and leukemias, provides the possibility to deplete B‑cells even in deep tissues. The initial results from case series with this procedure for SLE, myositis and systemic sclerosis were very positive. This review article gives an overview of the course, mechanism of action, results so far and the research agenda of CAR T‑cell therapy in autoimmune diseases.

Authors with CRIS profile

Melanie Hagen Department of Medicine 3 – Rheumatology and Immunology Jule Taubmann Department of Medicine 3 – Rheumatology and Immunology Fabian Müller Department of Medicine 5 – Haematology and Oncology Andreas Mackensen Lehrstuhl für Innere Medizin V Ricardo Grieshaber Bouyer Professur für Klinische Systemimmunologie Georg Schett Lehrstuhl für Innere Medizin III

How to cite

APA:

Hagen, M., Wirsching, A., Bohr, D., Taubmann, J., Müller, F., Mackensen, A.,... Schett, G. (2024). CAR-T-Zell-Therapie in der Rheumatologie – Was wissen wir bisher? Zeitschrift für Rheumatologie. https://doi.org/10.1007/s00393-024-01514-x

MLA:

Hagen, Melanie, et al. "CAR-T-Zell-Therapie in der Rheumatologie – Was wissen wir bisher?" Zeitschrift für Rheumatologie (2024).

BibTeX: Download